GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
ProvidersHealthRX
H
Provider prices

HealthRX

Compounding

Compare the published cost of each product and dose. Starting offers, maintenance prices, and membership fees can differ.

Loading offers…

Compare providersAll self-pay offers
Medication evidence:SemaglutideTirzepatide
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier

Search by medication, provider or treatment goal. Examples follow.

2 offers · US self-pay · 0 maintenance quotes

This order ignores commission. Partner links may earn us a referral fee.

ProductAdvertised priceMaintenance priceDetails
  • Compounded semaglutide via HealthRX

    Semaglutide · Compounded

    Compounded · Not FDA-approved
    Advertised pricefrom $99/mo

    28-day supply · 12-month upfront payment required

    ≈ $106.07 per 30 days at this quoted rate

    Checked Sep 30, 2026

    12-month plan billed $1,188 upfront; $133/mo on the 3-month plan; monthly: $149 first month, then $165

    Maintenance price

    No separate dose price verified

    View offer
    Price conditions & sourceChecked Sep 30, 2026

    Same price at every dose; each month is a 4-week vial supply. Consultation, medication and overnight shipping included; no membership fee. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.

    Read the advertised-price source
  • Compounded tirzepatide via HealthRX

    Tirzepatide · Compounded

    Compounded · Not FDA-approved
    Advertised pricefrom $179/mo

    28-day supply · 12-month upfront payment required

    ≈ $191.79 per 30 days at this quoted rate

    Checked Sep 30, 2026

    12-month plan billed $2,148 upfront; $209/mo on the 3-month plan; monthly: $193 first month, then $214

    Maintenance price

    No separate dose price verified

    View offer
    Price conditions & sourceChecked Sep 30, 2026

    Same price at every dose; each month is a 4-week vial supply. Consultation, medication and overnight shipping included; no membership fee. Compounded; not FDA-approved.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.

    Read the advertised-price source

Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.

Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.

The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.